Vertex Pharmaceuticals (VRTX) Initiated with a Buy at Cantor Fitzgerald
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...
ETF Daily News6d
Cantor Fitzgerald Has Weak Outlook for Amgen FY2025 Earnings
Cantor Fitzgerald analyst O. Brayer now forecasts that the medical research company will earn $20.67 per share for the year, down from their previous forecast of $21.44. Cantor Fitzgerald ...
Cantor Fitzgerald maintains Vertex stock Overweight rating
Cantor Fitzgerald reaffirmed its Overweight rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a consistent price target of $480.00. According to InvestingPro data, Vertex, a prominent ...
Business Insider21d
Vertex Pharmaceuticals (VRTX) Receives a Buy from Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed ...